<?xml version="1.0" encoding="UTF-8"?>
<p>Ma et al. reported BTA derivatives containing an 
 <italic>ortho</italic>-hydroxy-N-acyl hydrazone moiety for antiproliferative activities and procaspase-3 kinase activation activities against five different cell lines, namely MDA-MB-231 (human breast adenocarcinoma cell line), MNK-45 (gastric cancer cell line), NCI-H226 (human lung cancer cell line), HT-29 (human colorectal adenocarcinoma cell line) and SK-N-SH (neuroblastoma cell line). The substituted 2-hydroxybenzylidene containing semicarbazide 
 <bold>10</bold> (
 <xref ref-type="fig" rid="F0006">Figure 6</xref>) showed inhibitory activities against all cell lines with IC
 <sub>50</sub> and EC
 <sub>50</sub> values ranging from 0.24 to 0.92 µM and 0.31 µM respectively. The SAR studies revealed the paharmacological activities of BTA scaffold 
 <bold>10</bold> in 
 <italic>in-vitro</italic> is due to introduction of phenyl and benzyloxyl substitutions
 <xref rid="CIT0025" ref-type="bibr">
  <sup>25</sup>
 </xref>.
</p>
